Nova MD Review
Best for: patients comfortable with a 3-month plan commitment ($125/mo sema or $199/mo tirz) seeking the most competitive compounded pricing alongside an explicit microdose program and a multi-modality longevity menu
Nova MD (trynovamd.com) is a telehealth platform offering compounded GLP-1 (semaglutide) at $175/mo on a 1-month plan or $125/mo on a 3-month plan, and compounded GLP-1 + GIP (tirzepatide) at $225/mo on a 1-month plan or $199/mo on a 3-month plan with $50 off first order. Also offers a separate Microdosed GLP-1 Low-Dose Program plus Sermorelin, NAD+, Glutathione, and Enclomiphene. Site claims '1,241+ patients served', U.S.-licensed physicians, board-certified clinicians, HIPAA-compliant platform, and FSA/HSA eligibility on some plans. Prescribing model is asynchronous online assessment with same-day doctor review.
Medium confidence · Last verified 2026-05-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Nova MD is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Nova MD prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded GLP-1 / semaglutide (1-month plan) | compounded | $175 |
| Compounded GLP-1 / semaglutide (3-month plan) | compounded | $125 |
| Compounded GLP-1 + GIP / tirzepatide (1-month plan) | compounded | $225 |
| Compounded GLP-1 + GIP / tirzepatide (3-month plan) | compounded | $199 |
✓ Pros
- •Public, on-page pricing for all 4 SKUs (sema 1-mo, sema 3-mo, tirz 1-mo, tirz 3-mo) — material YMYL transparency advantage
- •$125/mo compounded semaglutide 3-month plan and $199/mo compounded tirzepatide 3-month plan are competitive with the cheapest decile of the US compounded telehealth market
- •$50 off first order on tirzepatide tier disclosed publicly
- •Microdose / low-dose program offered for both semaglutide and tirzepatide as a distinct SKU — uncommon explicit microdose offering
- •Multi-modality menu (Sermorelin, NAD+, Glutathione, Enclomiphene) for patients seeking longevity/strength alongside GLP-1
- •FSA/HSA eligibility disclosed (subject to plan specifics)
- •Same-day doctor review + cancel-anytime billing structure
✗ Cons
- •Specific legal entity name + state of incorporation NOT publicly disclosed
- •Partner compounding pharmacy NOT publicly named (described only as 'accredited facilities' / 'partner pharmacy')
- •LegitScript certification status NOT confirmed on the home page (only generic 'Licensed US Providers' / 'US Pharmacies' claims)
- •Per-state availability NOT enumerated
- •Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT offered — compounded only
- •Site is a fully client-side React/Vite SPA — content is not visible to standard server-side scrapers / search engines unless rendered via headless browser, which is a soft SEO + transparency signal
- •Lab work + ongoing monitoring inclusion NOT clearly disclosed
- •Patient-served count ('1,241+') is a marketing claim with no third-party verification; treat as directional not authoritative
Ready to start with Nova MD?
Starting at $125/month. See current pricing and start your free consultation.
Sources & methodology
Our Nova MD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Nova MD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Nova MD?
Starting at $125/month. See current pricing and start your free consultation.